UroGen Pharma (URGN) risk factors
Item 1A of every UroGen Pharma Ltd. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors89 risks7 new6 dropped29 reworded
Cash balances dropped from $241.7M to $120.5M while commercializing Jelmyto and Zusduri. New debt covenants restrict asset sales, dividends, and borrowing. Israeli operations face severe disruption risks from military reserve call-ups.
Filed Mar 02, 2026 - FY2024 10-K risk factors88 risks
UroGen is a biotechnology company heavily reliant on the commercial success of its sole approved product, Jelmyto, and its lead candidate, UGN-102. The company has a history of significant net losses, including $126.9 million in 2024, and depends on external financing and debt agreements. Operations are subject to extensive regulatory oversight, complex manufacturing requirements, and intense industry competition.
Filed Mar 10, 2025